{"id":"NCT04003636","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)","officialTitle":"A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-24","primaryCompletion":"2022-12-15","completion":"2025-04-01","firstPosted":"2019-07-01","resultsPosted":"2023-12-22","lastUpdate":"2025-04-23"},"enrollment":1069,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Biliary Tract Carcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475"]},{"type":"DRUG","name":"Gemcitabine","otherNames":["Gemzar"]},{"type":"DRUG","name":"Cisplatin","otherNames":["Platinol®","Platinol®-AQ"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arm A (Pembrolizumab+Gemcitabine+Cisplatin)","type":"EXPERIMENTAL"},{"label":"Arm B (Placebo+Gemcitabine+Cisplatin)","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. The primary hypothesis is pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to overall survival (OS).","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 38 months","effectByArm":[{"arm":"Arm A (Pembrolizumab+Gemcitabine+Cisplatin)","deltaMin":12.7,"sd":null},{"arm":"Arm B (Placebo+Gemcitabine+Cisplatin)","deltaMin":10.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0034"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":185,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","China","France","Germany","Hong Kong","Ireland","Israel","Italy","Japan","Malaysia","Netherlands","New Zealand","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["37075781","40268484","39206260","38661512"],"seeAlso":["https://www.merckclinicaltrials.com","https://msd.trialsummaries.com/Study/StudyDetails?id=26256&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":276,"n":529},"commonTop":["Neutrophil count decreased","Anaemia","Nausea","Platelet count decreased","Constipation"]}}